Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11558066 | 0.85 | GPR35 (0.59) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL28582931 | 0.85 | GPR35 (0.52) | ALDH1A1TDP1TSHRMAPK1CYP3A4 | |
| SCHEMBL7209289 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL6186321 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL7734435 | 0.82 | TSHR (0.48) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL4706779 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL20535866 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL29939725 | 0.80 | TDP1 (0.61) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL3650611 | 0.80 | TDP1 (0.61) | ALDH1A1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL10528040 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TDP1PDE7ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| CN-116514722-A | Benzimidazole derivatives as modulators of retinoic acid related orphan receptor gamma (ROR gamma) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3781161-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-3781161-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| CN-112135611-B | Benzimidazole derivatives as modulators of retinoic acid-related orphan receptor gamma (ROR γ) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-11-29 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2294066-B1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8759345-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2294066-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-03-16 | — | — | EP | disclosed |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009134750-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| US-6617315-B1 | Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty | CHAMBERLAIN STANLEY DAWES (US) | 2003-09-09 | — | — | US | disclosed |
| US-6204249-B1 | L-benzimidazole nucleosides | GLAXO WELLCOME INC. | 2001-03-20 | — | — | US | disclosed |
| EP-0876389-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997025337-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | ALDH1A1 46/4885TDP1 1767/4885PDE7A 1465/4885 |
| US-20110046132-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | ALDH1A1 32/4885TDP1 1567/4885PDE7A 1598/4885 |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | RORC, RORB, RORA | ALDH1A1 241/4885TDP1 4777/4885PDE7A 1649/4885 |
| US-20140005193-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | ALDH1A1 46/4885TDP1 1767/4885PDE7A 1465/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | ALDH1A1 3277/4885TDP1 2657/4885PDE7A 2663/4885 |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | RORC, RORB, RORA | ALDH1A1 244/4885TDP1 4783/4885PDE7A 1780/4885 |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | RORB, RORA, RORC | ALDH1A1 220/4885TDP1 4811/4885PDE7A 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.